New research suggests that both SGLT2 inhibitors and GLP-1 receptor agonists offer significant benefits for cardiovascular and kidney health in patients with type 2 diabetes, though there are nuances in their effects that may guide treatment decisions.
An observational study found no major differences in the overall impact of these drug classes on cardiovascular outcomes. However, SGLT2 inhibitors demonstrated a lower risk of severe kidney decline compared to GLP-1 receptor agonists, highlighting potential differences in their renal protective effects.
Key Findings:
Kidney Health: SGLT2 inhibitors were associated with a reduced risk of a 40% decline in estimated glomerular filtration rate (eGFR), a measure of kidney function, compared to GLP-1 receptor agonists. This suggests a superior renal benefit from SGLT2 inhibitors, as indicated by a better eGFR slope, which serves as a surrogate for kidney disease progression.
Cardiovascular Outcomes: There were no significant differences between the two drug classes in reducing risks of myocardial infarction (MI), stroke, or all-cause mortality. The findings were consistent for patients with and without chronic kidney disease (CKD) at baseline.
Safety and Side Effects: While SGLT2 inhibitors were linked to more frequent genital mycotic infections, the overall safety profile was similar for both drug classes.
Study Details:
The study, published in the Journal of the American College of Cardiology, utilized electronic health records from 20 US health systems. It included 82,272 patients with type 2 diabetes who were prescribed either an SGLT2 inhibitor or a GLP-1 receptor agonist between 2015 and 2020. The researchers applied a propensity score-weighted analysis to address potential confounding factors.
Guideline Implications:
European Guidelines: Both SGLT2 inhibitors and GLP-1 receptor agonists are recommended for patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) or CKD. SGLT2 inhibitors might have a slight preference in CKD management, but both drug classes are advised.
US Guidelines: Current guidelines favor GLP-1 receptor agonists with proven cardiovascular benefits in patients with CKD who do not achieve glycemic targets with other treatments. However, recent updates, including findings from the FLOW trial, may prompt a reevaluation of these recommendations.
Clinical Considerations:
For clinicians choosing between SGLT2 inhibitors and GLP-1 receptor agonists, SGLT2 inhibitors may be preferred for reducing the risk of kidney dialysis, whereas GLP-1 receptor agonists might be better for patients who also need weight loss or are at high risk for ASCVD.
Future Directions:
Experts Brendon Neuen and Scott Solomon emphasize the need to identify patients who would benefit most from either drug class. Increasing the use of these medications could have significant global health benefits, especially in preventing CKD progression and improving overall outcomes for patients with type 2 diabetes.
This study underscores the importance of individualized treatment strategies and the potential for both SGLT2 inhibitors and GLP-1 receptor agonists to play complementary roles in managing type 2 diabetes.
Related topics:
Scientists Unveil ‘Smart Insulin’: A Revolutionary Breakthrough in Diabetes Management
New Molecular Insights into Bariatric Surgery’s Impact on Obesity and Type 2 Diabetes
Lexicon Pharmaceuticals to Lay Off 50% of Workforce Amid Strategic Shift
